Takeda Oncology
Takeda Oncology, (originally Millennium Pharmaceuticals), is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.

Takeda Oncology's research, development and commercialization activities focused in two therapeutic areas: oncology and inflammation to develop a line of new product candidates. It was one of the first companies to systematically search for genes linked to disease, although none of the drugs which it is marketing or has in clinical trial, with one partial exception, have been the results of that research.

It is particularly known for bringing bortezomib (marketed as Velcade) through clinical trials to approval for treatment of patients with multiple myeloma by the U.S. FDA, but has a growing clinical development pipeline of other product candidates.

On May 14, 2008, Japanese company Takeda Pharmaceutical announced the completion of its acquisition of Millennium for US$25.00 per share in cash—a deal worth $8.8 billion. Takeda completed the acquisition through a tender offer and subsequent merger as a wholly owned subsidiary Millennium: The Takeda Oncology Company - with the name being simplified to Takeda Oncology in 2013.
Q49111
Cambridge
LOC
Q771
Massachusetts
LOC
Q899133
Takeda Pharmaceutical
ORG
Q42240
research
Concept
Q179661
therapeutic
Concept
Q162555
oncology
Concept
Q101991
inflammation
Concept
Q419319
bortezomib
Concept
Q419319
Velcade
Concept
Q467635
multiple myeloma
Concept
Q7404325
pipeline
UNK
Q6858915
Takeda Oncology
ORG
Q6858915
Takeda Oncology
ORG
Q6858915
Takeda Oncology
ORG
Q6858915
Takeda Oncology
ORG
2008-05-14T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
May 14, 2008
DATE
2013-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2013
DATE
+25.00^^http://www.w3.org/2001/XMLSchema#decimal
25.00
NUMBER
+8.8^^http://www.w3.org/2001/XMLSchema#decimal
8.8
NUMBER
headquarters location
medical condition treated
medical condition treated